Astria Therapeutics, Inc. (NASDAQ:ATXS) Q4 2022 Earnings Conference Call March 22, 2023 8:30 AM ET

Company Participants

Andrea Matthews - Senior Vice President, Corporate Affairs

Jill Milne - Chief Executive Officer

Andy Nichols - Chief Scientific Officer

Andrew Komjathy - Chief Commercial Officer

Chris Morabito - Chief Medical Officer

Noah Clauser - Chief Financial Officer

Conference Call Participants

Hartaj Singh - Oppenheimer

Oliver McCammon - LifeSci Capital, LLC

Joe Pantginis - H.C. Wainwright

Eun Yang - Jefferies

Michael Higgins - Ladenburg Thalmann

Operator

Good morning and welcome to the Astria Therapeutics 2022 Q4 and Full Year Financial Results and Business Update Conference Call. At this time, all attendees are in a listen-only mode. A question-and-answer session will follow the formal presentations. As a reminder, this call is being recorded, and a replay will be made available on the Astria Therapeutics website for 90 days following the conclusion of the event.

I would now like to turn the call over to Andrea Matthews, Senior Vice President of Corporate Affairs at Astria Therapeutics. Please go ahead, Andrea.

Andrea Matthews

Thank you, operator. Welcome to today’s Astria Therapeutics conference call, where we will provide a corporate update and review our fourth quarter and full year 2022 financial results.

With me today are; Jill Milne, Chief Executive Officer; Andy Nichols, Chief Scientific Officer; Andrew Komjathy, Chief Commercial Officer; Chris Morabito, Chief Medical Officer; and Noah Clauser, Chief Financial Officer.

We issued a press release this morning summarizing our corporate update and our Q4 full year 2022 financial results, which we will reference on today's call is available on our website. We are also using slides during today's call that are available within the Events and Presentations section of the Investors part of our website.

I would like to note that during today's call, as mentioned on Slide 2, we will make forward-looking statements related to our business based on current and future expectations that may be considered -- sorry, actual results may differ from those indicated including those discussed in our most recent annual report on Form 10-K as well as discussions of potential risks, uncertainties and other important factors in subsequent SEC filings, which will be available on our website. Such statements represent our judgment as of today, and Astria undertakes no obligation to publicly update any forward-looking statements, except as required by law.

With that, let me pass the call over to Jill, who will provide our corporate update. Andrew will discuss the HAE market opportunity. Chris will go through the Phase 1a safety and PK results and the ALPHA-STAR trial, and Andy will discuss the PD data. Noah will follow with the financial update. Jill will then wrap things up. Jill?